DNB Asset Management AS Sells 3,320 Shares of McKesson Corporation $MCK

DNB Asset Management AS reduced its position in shares of McKesson Corporation (NYSE:MCK) by 7.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,957 shares of the company’s stock after selling 3,320 shares during the quarter. DNB Asset Management AS’s holdings in McKesson were worth $33,959,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in McKesson in the second quarter worth approximately $1,346,661,000. Alliancebernstein L.P. raised its holdings in shares of McKesson by 150.4% in the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after acquiring an additional 446,060 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of McKesson by 45.6% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after purchasing an additional 261,296 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in McKesson by 68.0% during the 2nd quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock valued at $466,441,000 after acquiring an additional 257,670 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares in the company, valued at $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Thomas L. Rodgers sold 276 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,143 shares of company stock worth $1,046,070 in the last quarter. Insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on MCK. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. TD Cowen raised their price objective on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a report on Thursday, February 5th. Robert W. Baird set a $968.00 price objective on McKesson in a research report on Wednesday, January 14th. Weiss Ratings lowered McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Finally, Zacks Research lowered shares of McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $943.50.

McKesson Price Performance

NYSE MCK opened at $984.61 on Friday. The stock’s 50 day simple moving average is $868.77 and its 200-day simple moving average is $805.52. The company has a market cap of $120.60 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 1.57 and a beta of 0.40. McKesson Corporation has a 1-year low of $621.88 and a 1-year high of $987.37.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same period in the prior year, the company earned $8.03 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities research analysts anticipate that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is currently 9.43%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.